Edition:
United States

Moleculin Biotech Inc (MBRX.OQ)

MBRX.OQ on NASDAQ Stock Exchange Capital Market

2.07USD
16 Feb 2018
Change (% chg)

$-0.73 (-26.07%)
Prev Close
$2.80
Open
$2.16
Day's High
$2.27
Day's Low
$2.00
Volume
1,736,360
Avg. Vol
137,167
52-wk High
$3.74
52-wk Low
$0.71

Chart for

About

Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).... (more)

Overall

Beta: --
Market Cap(Mil.): $43.75
Shares Outstanding(Mil.): 21.14
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.03 17.27
EPS (TTM): -- -- --
ROI: -- 14.00 35.43
ROE: -- 15.34 17.10

BRIEF-Moleculin Biotech Inc - Has Been Able To Show Promising Tumor Suppression Activity With Its Inhibitor Of Glycolysis, Wp1122

* MOLECULIN BIOTECH INC - HAS BEEN ABLE TO SHOW PROMISING TUMOR SUPPRESSION ACTIVITY WITH ITS INHIBITOR OF GLYCOLYSIS, WP1122 Source text for Eikon: Further company coverage:

Feb 07 2018

BRIEF-Moleculin Expands Leukemia Development Portfolio With Immuno-Stimulating Stat3 Inhibitor

* MOLECULIN EXPANDS LEUKEMIA DEVELOPMENT PORTFOLIO WITH IMMUNO-STIMULATING STAT3 INHIBITOR

Jan 10 2018

BRIEF-Moleculin Announces Polish Approval For Leukemia Clinical Trial

* MOLECULIN ANNOUNCES POLISH APPROVAL FOR LEUKEMIA CLINICAL TRIAL

Dec 21 2017

BRIEF-Moleculin Biotech Says Co Was Informed That Investigational NDA For Phase I Trial Of WP1066 Has Been Allowed By FDA

* MOLECULIN BIOTECH SAYS ON NOV 29, CO WAS INFORMED THAT INVESTIGATIONAL NDA FOR PHASE I TRIAL OF WP1066 HAS BEEN ALLOWED BY FDA - SEC FILING Source text: [http://bit.ly/2jcVpeo] Further company coverage:

Dec 04 2017

BRIEF-Moleculin Biotech Q3 loss per share $0.14‍​

* Moleculin Biotech Inc reports financial results for the third quarter ended september 30, 2017

Nov 14 2017

BRIEF-Moleculin appoints Sandra Silberman as chief medical officer

* Moleculin appoints Dr. Sandra Silberman as chief medical officer -- new products Source text for Eikon: Further company coverage:

Nov 08 2017

BRIEF-Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors

* Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors

Nov 01 2017

BRIEF-Moleculin requests for clinical trial authorization to study annamycin

* Moleculin Biotech - ‍submitted request for clinical trial authorization to study annamycin for treating relapsed/refractory acute myeloid leukemia in Poland Source text for Eikon: Further company coverage:

Oct 24 2017

BRIEF-Moleculin announces strategic collaboration to develop immune stimulation drug

* Moleculin announces strategic collaboration to develop immune stimulation drug

Oct 11 2017

BRIEF-Moleculin announces FDA approval of Annamycin IND

* Moleculin Biotech - ‍U.S. IND allows Moleculin to make submission to Polish authorities for planned Annamycin clinical trial to be conducted in Poland​ Source text for Eikon: Further company coverage:

Sep 26 2017

Earnings vs. Estimates